Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:ADC |
favorable
|
| gptkbp:behavior |
improves mood
|
| gptkbp:built |
regulatory hurdles
|
| gptkbp:campusFacilities |
gptkb:XYZ_University
|
| gptkbp:chemicalFormula |
thiazole derivatives
lipophilic thiazole ring C20H22N2O2S stable in solution |
| gptkbp:classification |
novel antidepressant
|
| gptkbp:clinicalTrials |
ongoing
potentially significant |
| gptkbp:collaborations |
gptkb:ABC_Pharmaceuticals
international collaboration |
| gptkbp:compatibleWith |
antidepressant
|
| gptkbp:composedOf |
multi-step organic synthesis
|
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:environmentalImpact |
low toxicity
|
| gptkbp:fauna |
rat model of depression
|
| gptkbp:financial_aid |
stable under normal conditions
|
| gptkbp:firstClaim |
treatment of anxiety
|
| gptkbp:formulation |
oral administration
|
| gptkbp:funding |
government grant
|
| gptkbp:future_plans |
further studies required
|
| https://www.w3.org/2000/01/rdf-schema#label |
SR 835
|
| gptkbp:impact |
unknown
|
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:market |
not marketed
|
| gptkbp:operational_status |
investigational new drug
preclinical |
| gptkbp:origin |
N-(4-(4-(dimethylamino)phenyl)-2-methylphenyl)-2-methyl-2-(4-methylphenyl)thiazole-4-carboxamide
|
| gptkbp:patentAssignee |
gptkb:XYZ_University
|
| gptkbp:patentStatus |
patented
|
| gptkbp:publications |
gptkb:Journal_of_Neuroscience
|
| gptkbp:regulatoryBody |
high affinity
|
| gptkbp:related_to |
SR 57746A
|
| gptkbp:releaseYear |
2000
|
| gptkbp:research_areas |
psychiatry
|
| gptkbp:research_focus |
discovery phase
mood disorders |
| gptkbp:researchAndDevelopment |
promising results
|
| gptkbp:safety_features |
not fully established
|
| gptkbp:safetyFeatures |
required
|
| gptkbp:storage |
cool, dry place
|
| gptkbp:targets |
5-HT receptor
serotonin receptor |
| gptkbp:triggerType |
serotonin reuptake inhibition
|
| gptkbp:uses |
research in neuroscience
|
| gptkbp:weight |
350.47 g/mol
|